Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL
Johnson & Johnson’s BTK inhibitor Imbruvica plus AbbVie and Roche’s Vencylxto demonstrated superiority over Gazyva plus chemotherapy in a new Phase III study.
In...
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingExploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingExploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingHighlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement